• News

IO Biotech enters clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDA® (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer

Copenhagen, Denmark – March 12, 2018: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win technology, announces it has entered into a collaborative agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), through a subsidiary, focused on the clinical evaluation of IO102 with KEYTRUDA® (pembrolizumab) in patients with non-small cell lung cancer (NSCLC)

Continue Reading